News
Open call for Oncode investigator applications
Oncode Institute has opened a call for applications for their Oncode Recruitment Programme. Up to eleven scientists will be awarded base-funding for the remaining duration of the first phase of Oncode, ending in September 2022.
Module Clinical Development
The module Clinical Development at Paul Janssen Futurelab Leiden provides learning-by-doing training to ambitious -postgraduate biomedical researchers. During this program, you will further your career and increase your knowledge on the optimal development of novel medical interventions, using real life cases. Ready to go on-campus?
Top Sector LSH and SGF invest 15 million in immunology research
De Samenwerkende Gezondheidsfondsen (SGF), waarin 20 gezondheidsfondsen waaronder KWF Kankerbestrijding en ReumaNederland de krachten hebben gebundeld, investeren samen met Topsector Life Sciences & Health (Health~Holland) en het bedrijfsleven 15 miljoen euro in veelbelovende immunologische onderzoeken. De onderzoeken moeten de werking van het menselijke afweersysteem verder ontrafelen.
Health & Care officially assigned as central theme in the mission driven innovation policy
On 13 July the Ministerial Council officially approved the new Mission Driven Innovation Policy that builds upon the Top Sector Policy, with a clear focus on global societal challenges. Health & Care is appointed as one of the four central themes in the renewed Top Sector Policy. Top Sector Life Sciences & Health (LSH) celebrates this good news for the Dutch LSH sector. The importance of this sector and the strong innovative solutions it offers are now officially recognised by the government.
GlobalStars stimulating market-oriented R&D with partners outside Europe
Bent u bezig met het ontwikkelen van technologie voor nieuwe producten, processen of diensten? Werkt u daarbij samen met partners buiten Europa? Dan is GlobalStars mogelijk iets voor u.European consortium ella4life helps elderly live independently for longer
Bedrijven, universiteiten en zorginstellingen uit Nederland, Polen, Roemenië en Zwitserland werken de komende drie jaar samen in een Europees AAL Programma van 1.9 miljoen euro: Ella4Life. Twee gevalideerde medische hulpmiddelen, Anne en Emma, worden gecombineerd tot slimme assistent Ella om ouderen te helpen zo lang mogelijk zelfstandig thuis te blijven wonen.
Carduso Capital invests in CC Diagnostics
Carduso Capital investeert in de Groningse onderneming CC Diagnostics B.V. die met haar technologie een verhoogd risico op het ontwikkelen van baarmoederhalskanker nauwkeurig aan kan tonen. De basis van de onderneming vormt een wereldwijd gepatenteerde test die is ontwikkeld in het UMCG. De ontwikkelde test meet en interpreteert unieke DNA-afwijkingen die geassocieerd zijn met de ontwikkeling van baarmoederhalskanker. Het Groningse bedrijf zal zich medio 2018 vestigen aan de L.J. Zielstraweg 1.
Carduso Capital invests in “AGILeBiotics”
Carduso Capital invests in the Groningen start-up AGILeBiotics that is applying its platform technology, developing new antibiotics in the fast-growing markets of hospital-treated multidrug-resistant infections. The founding of AGILeBiotics is based on the worldwide patented platform ‘OxaSelect’, which gives quick access to various novel antibiotics based on an existing drug class. The technology was developed within the RUG. With OxaSelect a broad variety of drug candidates can be generated, leading to new antibiotics for the treatment of hospitalized patients infected by multidrug-resistant Gram-negative bacteria.
Dutch Heart Foundation, UMC Groningen and Pivot Park Screening Centre collaborate on heart failure
Scientists from UMC Groningen and Pivot Park Screening Centre have started a study with the objective to prevent one of the causes of heart failure. It is the first time that a protein related to protection of the heart muscle from stiffening, will be screened to discover a starting point for development of a new medicine. The study builds on the earlier work by cardiologist Van der Meer and his team. Pivot Park Screening Centre’s ultra High Throughput Screening facilities and expertise are used to discover matches between the protein and compounds. This collaboration is financed by Top Sector Life Sciences & Health (designated by the Dutch Ministry of Economic Affairs and Climate Policy in 2011) to stimulate Public-Private Partnerships and is supported by the Dutch Heart Foundation (Hartstichting).ProPharma Group Announces the Acquisition of Xendo
ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Xendo Holding B.V. (“Xendo”), a Netherlands-based provider of compliance consulting, engineering & technical support, regulatory affairs, and pharmacovigilance services to the (bio)pharmaceutical, medical device and healthcareindustries. The acquisition of Xendo also includes Sofus Regulatory Affairs AB, based in Sweden. “We are excited to support the entire ProPharma Group organization as they continueto build out capabilities and expand their global presence to better serve their customers”, saidMichael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners.